09:28 AM EST, 12/10/2024 (MT Newswires) -- NewAmsterdam Pharma ( NAMS ) said Tuesday a phase 3 trial assessing obicetrapib in people with established atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia reached its primary endpoint.

The company's shares surged 35% in recent premarket activity.

The primary endpoint was the least-squares mean of the percent change in LDL-C from baseline to day 84 for obicetrapib 10 milligrams compared with placebo, the company said, adding the primary goal was reached with "statistical significance with an LDL-C reduction of 33%."

Also, obicetrapib was well-tolerated, with safety results, including blood pressure, comparable to placebo, the company said.